Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.
Twenty-eight patients with refractory adult acute leukemia were treated with pyrazofurin and 5-azacytidine. Seven patients showed a response. Dermatitis and mucositis were severe at doses of pyrazofurin greater than 50 mg/m2/day and precluded administration of multiple courses in most patients. As a result of this toxicity, 16 patients received only one course of chemotherapy. The response rates achieved with this combination were not superior to those achieved with 5-azacytidine alone.
D000577:Amides; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D004341:Drug Evaluation; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D007938:Leukemia / Q000188:drug therapy*; D009092:Mucous Membrane / Q000187:drug effects; D011379:Prognosis; D011720:Pyrazoles; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D012266:Ribose
D000577:Amides; D000970:Antineoplastic Agents; D011720:Pyrazoles; D012263:Ribonucleosides; C002997:pyrazofurin; D012266:Ribose; D001374:Azacitidine